Published in final edited form as:

Biochem Pharmacol. 2010 March 1; 79(5): 733–745. doi:10.1016/j.bcp.2009.10.014.

Angiotensin-induced EGF receptor transactivation inhibits insulin signaling in C9 hepatic cells

Araceli Arellano-Plancarte^a, Judith Hernandez-Aranda^a, Kevin J. Catt^b, and J. Alberto Olivares-Reyes^{a,*}

^aDepartment of Biochemistry, Center for Research and Advanced Studies of the National Polytechnic Institute, Cinvestav-IPN, A.P. 14-740, Mexico, 07360 D.F., Mexico

^bSection on Hormonal Regulation, PDEGEN, National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892, USA

Abstract

To investigate the potential interactions between the angiotensin II (Ang II) and insulin signaling systems, regulation of IRS-1 phosphorylation and insulin-induced Akt activation by Ang II were examined in clone 9 (C9) hepatocytes. In these cells, Ang II specifically inhibited activation of insulin-induced Akt Thr³⁰⁸ and its immediate downstream substrate GSK-3 α/β in a time-dependent fashion, with ~70% reduction at 15min. These inhibitory actions were associated with increased IRS-1 phosphorylation of Ser⁶³⁶/Ser⁶³⁹ that was prevented by selective blockade of EGFR tyrosine kinase activity with AG1478. Previous studies have shown that insulin-induced phosphorylation of IRS-1 on Ser⁶³⁶/Ser⁶³⁹ is mediated mainly by the PI3K/mTOR/S6K-1 sequence. Studies with specific inhibitors of PI3K (wortmannin) and mTOR (rapamycin) revealed that Ang II stimulates IRS-1 phosphorylation of Ser⁶³⁶/Ser⁶³⁹ via the PI3K/mTOR/S6K-1 pathway. Both inhibitors blocked the effect of Ang II on insulin-induced activation of Akt. Studies using the specific MEK inhibitor, PD98059, revealed that ERK1/2 activation also mediates Ang II-induced S6K-1 and IRS-1 phosphorylation, and the impairment of Akt Thr³⁰⁸ and GSK-3 α/β phosphorylation. Further studies with selective inhibitors showed that PI3K activation was upstream of ERK, suggesting a new mechanism for Ang II-induced impairment of insulin signaling. These findings indicate that Ang II has a significant role in the development of insulin resistance by a mechanism that involves EGFR transactivation and the PI3K/ERK1/2/mTOR-S6K-1 pathway.

Keywords

Angiotensin II; Insulin; EGF receptor transactivation; Insulin resistance; Akt

© 2009 Elsevier Inc. All rights reserved.

*Corresponding author at: Laboratory of Signal Transduction, Department of Biochemistry, Cinvestav-IPN, Mexico, 07360 D.F., Mexico. Tel.: + 52 55 5747 3951; fax: + 52 55 5747 3391. jolivare@cinvestav.mx (J.A. Olivares-Reyes).

Conflict of interest

None.

1. Introduction

Insulin, the most potent anabolic hormone, is essential for optimal tissue development and growth, and the maintenance of glucose homeostasis. Insulin action is mediated through a complex network of signaling events initiated when the hormone binds to its cell-surface receptors. Activation of the insulin receptor (IR) triggers its intrinsic protein-tyrosine (Tyr) kinase activity, resulting in autophosphorylation of several IR Tyr residues and the recruitment and phosphorylation of IR substrate (IRS) proteins [1]. After Tyr phosphorylation, IRS acts as docking protein for several Src homology 2 (SH2) domain-containing molecules, including Grb2, the small adapter protein Nck, the tyrosine phosphatase Syp, phosphatidylinositol 3-kinase (PI3K), and others [1,2].

PI3K has a central role downstream of the IRS proteins in the activation and regulation of many insulin-induced metabolic processes. During its association with IRS, PI3K promotes the activation of Akt (PKB) that regulates multiple biological processes. These include stimulation of glucose transport, glycogen and protein synthesis, cellular proliferation and survival through regulation of additional kinases such as the glycogen synthase kinase-3 α/β (GSK-3 α/β), FOXO1, BAD, TSC2 and AS160 [1–5].

The duration and extent of signals induced by insulin are tightly regulated to promote optimal insulin actions in the body, and impaired generation of these signals causes a common pathological state termed insulin resistance. This occurs in a wide variety of pathological states, including obesity, hypertension, chronic infection and cardiovascular diseases, and is a central component of non-insulin dependent diabetes mellitus or Type 2 Diabetes Mellitus (DM2) [6–9].

It has been proposed that multiple phosphorylation of IRS proteins in serine/threonine (Ser/Thr) residues has a key role in the inhibition of insulin signaling by both physiological and patho-physiological activation of a negative feedback mechanism [10]. Interestingly, many factors that enhance Ser/Thr phosphorylation of IRS proteins have been implicated in the development of insulin resistance. These include endothelin [11], TNF α [12], free fatty acids [13] and Ang II [14].

Ang II, the major effector hormone of the renin–angiotensin system (RAS), has an important role in the regulation of vascular and renal homeostasis. The actions of Ang II are initiated by its interaction with two GPCRs, the AT₁ and the AT₂ receptor subtypes (AT₁R and AT₂R) [15]. The majority of the biological and pathological actions of Ang II are mediated by the AT₁R, which signals via G_{q/11} to activate phospholipase C- β . The subsequent generation of second messengers such as diacylglycerol (DAG) and inositol trisphosphate (IP₃), in turn stimulate the activity of the protein PKC and mobilize Ca²⁺ from intracellular reservoirs [15]. This signaling pathway is the primary transduction mechanism initiated by the AT₁R in its major physiological tissues, including adrenal, neuronal, cardiac, renal, hepatic and smooth muscle cells [15,16]. In recent years, several reports have shown that AT₁Rs are also connected to signaling pathways usually associated with growth factor and cytokine receptors. This occurs mainly through AT₁R coupling to transactivation of

epidermal growth factor receptors (EGFRs) to mediate critical cellular events such as growth, proliferative and antiproliferative effects, and migration [15,17–19].

Recent clinical and pharmacological studies have shown that Ang II induces insulin resistance, and that Ang II-converting enzyme inhibitors (ACEIs) and AT₁R blockers (ARBs) improve insulin sensitivity [5,20–22]. These findings suggest that over-activity of the RAS impairs insulin signaling and contributes to insulin resistance. Furthermore, Ang II also induces Ser phosphorylation of IRS-1 by ERK1/2 and PKC at Ser³¹² and Ser⁶¹⁶, leading to the impairment of PI3K and Akt activation [5,14,23–25]. Although phosphorylation of IRS-1 at Ser³¹² and Ser⁶¹⁶ impairs insulin signaling, recent reports indicate that phosphorylation of IRS-1 on Ser⁶³⁶/Ser⁶³⁹ has a major inhibitory action on the development of DM2 in humans [26]. In this context, Khamzina et al. [27] reported that insulin activation of the mammalian target of rapamycin (mTOR) and ribosomal S6 kinase-1 (S6K-1) inhibits insulin signaling to the PI3K/Akt pathway in hepatic cells, possibly by increased inhibitory phosphorylation of IRS-1 on Ser⁶³⁶/Ser⁶³⁹ [27]. They also showed that mTOR and S6K-1 activation are increased in the liver and skeletal muscle of high fat-fed, obese rats, implicating these Ser/Thr kinases as potential mediators of insulin resistance [27].

The actions of Ang II on insulin sensitivity have been mainly described in cardiovascular cell models, since insulin resistance has been considered as an important risk factor in the development of cardiovascular diseases such as hypertension and atherosclerosis [14,24,25,28]. Although in insulin resistant states, insulin action is also impaired in the liver, skeletal muscle and adipose tissue, relatively few studies have explored the effect of Ang II on the development of insulin resistance in those tissues [3,29–31]. In this context, hepatic insulin resistance is an important underlying cause of the metabolic syndrome that manifests itself in diseases such as DM2, atherosclerosis and non-alcoholic fatty liver disease [32]. In the present study, an analysis of Ang II action in a hepatic cell line was performed to seek insights into the molecular mechanism by which Ang II interferes with insulin action leading to impairment of insulin.

2. Materials and methods

2.1. Reagents and antibodies

F-12K nutrient mixture (Kaighn's modification), fetal bovine serum (FBS), trypsin, and antibiotic/amphotericin B solutions and EGF were from Invitrogen-GIBCO (Carlsbad, CA, USA). Ang II was from BACHEM (Torrance, CA, USA); insulin, wortmannin, LY-294002 [2-(4-morpholinyl)-8-phenyl-(4H)-1-benzopyran-4-one], AG1478 (tyrphostin), GM6001 and rapamycin were from Sigma (St. Louis, MO, USA). Bisindolylmaleimide I, PD98059 and lactacystin were from Calbiochem (La Jolla, CA, USA). Losartan (DuP 753) was a generous gift from DuPont (Wilmington, DE, USA). ECL reagents were from GE Healthcare (Buckinghamshire, UK) or Immobilon™ Millipore Corporation (Billerica, MA, USA). Anti-phospho-ERK1/2 Thr²⁰²/Tyr²⁰⁴ (anti-p-ERK1/2 Thr²⁰²/Tyr²⁰⁴), anti-phospho-IRS-1 Ser⁶³⁶/Ser⁶³⁹ (anti-p-IRS-1 Ser⁶³⁶/Ser⁶³⁹), anti-IRS-1, anti-GSK-3 β and anti-phospho-GSK-3 α/β Ser^{21/9} (anti-p-GSK α/β Ser^{21/9}) were obtained from Cell Signaling Technology (Beverly, MA, USA). Anti-phospho-p70 S6K-1 Thr⁴²¹/Ser⁴²⁴ (anti-p-S6K-1

Thr⁴²¹/Ser⁴²⁴), anti-phospho-Akt Thr³⁰⁸ (anti-p-Akt Thr³⁰⁸), anti-IR (β -subunit), anti-p70 S6K-1 (anti-S6K-1) and anti-ERK were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phospho-Akt Ser⁴⁷³ (anti-p-Akt Ser⁴⁷³) was from UPSTATE (Lake Placid, NY, USA). Polyclonal and monoclonal antibodies were purchased from Invitrogen-Zymed (Carlsbad, CA, USA).

2.2. Cell culture

C9 rat liver epithelial cells obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA) were grown in Ham's F-12K nutrient mixture (Kaighn's modification) supplemented with 10% (v/v) FBS, 100 μ g/ml streptomycin, 100IU/ml penicillin, and 0.25 μ g/ml amphotericin B at 37 °C in 95% air and 5% CO₂. For all studies, C9 cells between passages 3 and 12 were used because they exhibit maximum expression of their endogenous AT1 receptors [17]. For experiments, cells were re-seeded on six- and twelve-well plates. Before experiments, C9 cells were maintained in low serum medium for 16 h, and then switched to serum-free medium for 3 h.

2.3. Immunoblot analysis

C9 cells were grown in six- or twelve-well plates in F-12K nutrient mixture (Kaighn's modification) supplemented with 10% FBS. At 70–80% confluence, C9 cells were grown in 2% serum/F-12K nutrient mixture for 16 h, then media were changed to serum-free media for 3 h before treatment with the indicated ligands and inhibitors. After treatment, cells were placed on ice, the media were aspirated, and the cells were washed twice with ice-cold PBS and lysed in 100 μ l of Laemmli sample buffer 1 $\times$. The samples were briefly sonicated, heated at 99 °C, and centrifuged for 5 min at 12,000 rpm. The supernatant was electrophoresed on SDS-PAGE (8 or 10%) gels and transferred to PVDF nylon membranes. Blots were incubated overnight at 4 °C with primary antibodies and washed three times with TBST before probing with horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature. Blots were then visualized with ECL [enhanced chemiluminescence reagent]. Autoradiograms were scanned using the GS-800 Calibrated Imaging Densitometer (Bio-Rad, Hercules, CA, USA), and the labeled bands were quantified using the Quantity One 4.6.3 software program (Bio-Rad, Hercules, CA, USA).

2.4. Statistical analysis

Measurements of intensity from Western blots were analyzed using either one- or two-way ANOVA with Dunnett and Bonferro-ni's post-test using PRISM, version 4.0 (GraphPad Software, San Diego, CA, USA). In all cases, $p < 0.05$ was considered to be significant. Resultant data were plotted on bar graphs, with data expressed as mean $\pm$ S.E.M. percentage from at least three separate experiments, and representative blots are shown as needed.

3. Results

3.1. Insulin induces Akt phosphorylation at Thr³⁰⁸ and Ser⁴⁷³

We first determined the effect of insulin on phosphorylation of Akt at Thr³⁰⁸ and Ser⁴⁷³ in hepatic C9 cells, where insulin caused rapid and marked phosphorylation of Akt at both sites (Fig. 1A). However, important differences in the maximum effect and temporality of

phosphorylation were observed. Insulin-induced Akt Ser⁴⁷³ phosphorylation was relatively sustained, reaching a maximum (~200%) at 5 min, and persisted for up to 60 min or longer. In contrast, insulin-induced Akt Thr³⁰⁸ phosphorylation reached a maximum (about 350%) after 15 min and then declined over 30–60 min without reaching the basal phosphorylation level of Akt.

To determine the ability of Akt to regulate its immediate downstream substrate, glycogen synthase kinase-3 α/β (GSK-3 α/β), we evaluated phosphorylation and inactivation of GSK-3 α/β in C9 cells. GSK-3 α/β is a key regulatory enzyme of glycogen synthesis and represents one of the main insulin substrates in hepatic tissue. As expected, insulin caused rapid GSK-3 α/β phosphorylation that reached a maximum (~200%) at 15 min and declined over 45–60 min without reaching the basal phosphorylation level (Fig. 1B).

3.2. Ang II desensitizes insulin signaling

Since several reports have demonstrated that impairment of insulin-induced Akt phosphorylation is an important event in insulin resistance [30,32,34], we determined whether Ang II impairs insulin-induced Akt phosphorylation in C9 cells. As shown in Fig. 1C, incubation of cells with 100 nM Ang II from 5 to 60 min, followed by addition of 100 nM insulin for 15 min, reduced insulin-induced Akt phosphorylation on both Ser⁴⁷³ and Thr³⁰⁸. Interestingly, the impairment of Akt phosphorylation by Ang II on these two sites was different: while Ang II inhibited Thr³⁰⁸ phosphorylation by about 70% ($p < 0.001$), Ser⁴⁷³ phosphorylation was inhibited by only 40% ($p < 0.001$). These data indicate for the first time that Ang II differentially affects the phosphorylation of Akt at Thr³⁰⁸, a crucial residue involved in the Akt-induced metabolic actions of insulin [31,34].

To determine whether the effect of Ang II on insulin-induced Akt phosphorylation affects GSK-3 α/β regulation, we examined the phosphorylation state of GSK-3 α/β . As expected, phosphorylation of GSK-3 α/β by insulin was diminished by pretreatment with Ang II for 15 or 60 min (Fig. 1D), indicating the ability of Ang II to desensitize insulin signaling and its downstream effectors.

3.3. Ang II induces phosphorylation of IRS-1 at Ser⁶³⁶/Ser⁶³⁹

Previous studies have shown the relevance of phosphorylation of IRS at Ser⁶³⁶/Ser⁶³⁹ as a key mechanism in the impairment of insulin actions [35,36]. We therefore determined whether Ang II could induce IRS-1 phosphorylation in C9 cells. We first examined the effect of insulin on IRS-1 Ser⁶³⁶/Ser⁶³⁹ phosphorylation in a control experiment, since this constitutes a mechanism of homologous desensitization in several cell types. As shown in Fig. 2A, IRS-1 phosphorylation at Ser⁶³⁶/Ser⁶³⁹ was increased by insulin, reaching maximal activation (~230%) at 15 min and then declining over the next 45 min without reaching the basal level (~170% at 60 min). Interestingly, Ang II also increased IRS-1 Ser⁶³⁶/Ser⁶³⁹ phosphorylation in a time- and concentration-dependent manner. Ang II promoted IRS-1 phosphorylation with a maximal increase of ~2-fold at 100 nM (Fig. 2B) that rapidly peaked at 5 min (~230%) and then declined after 15 min in a time-dependent manner (Fig. 2A).

3.4. Ang II causes phosphorylation of IRS-1 through the mTOR/S6K-1 pathway

Activation of mTOR/p70 S6 kinase-1 has emerged as the critical event in rendering IRS-1 unresponsive to insulin, mainly through phosphorylation of IRS-1 on Ser⁶³⁶/Ser⁶³⁹ [27,37]. To determine whether p70 S6 kinase-1 (S6K-1) might be the kinase involved in insulin- and Ang II-induced IRS-1 Ser⁶³⁶/Ser⁶³⁹ phosphorylation, we used a phospho-specific antibody that detects S6K-1 when it is phosphorylated at Thr⁴²¹/Ser⁴²⁴ in the auto-inhibitory domain [38]. C9 cells exposed to insulin showed a time- and dose-dependent S6K-1 phosphorylation that reached a maximum at 100 nM (~250%) (Fig. 3A) after 15 min stimulation that was maintained up to 60 min (Fig. 3B). In contrast, although Ang II increased phosphorylation of S6K-1, the maximum effect observed was lower than that caused by insulin, in a range between 1 and 1000 nM (~200%) (Fig. 3A). Interestingly, Ang II-induced S6K-1 phosphorylation peaked at 5 min and then decreased in a time-dependent manner (Fig. 3B).

S6K-1 is a downstream target of mTOR, a critical kinase involved in metabolic disorders and tumorigenesis [39]. To determine whether IRS-1 Ser⁶³⁶/Ser⁶³⁹ phosphorylation is mediated by mTOR/S6K-1, C9 cells were preincubated with the specific mTOR inhibitor, rapamycin (100 nM) for 30 min, and then stimulated with insulin and Ang II. As expected, insulin- and Ang II-induced S6K-1 Thr⁴²¹/Ser⁴²⁴ phosphorylation was completely inhibited by rapamycin treatment. Furthermore, rapamycin also inhibited insulin- and Ang II-induced IRS-1 Ser⁶³⁶/Ser⁶³⁹ phosphorylation (Fig. 3C). These data suggest that in C9 cells the mTOR/ S6K-1 pathway is necessary for IRS-1 Ser⁶³⁶/Ser⁶³⁹ phosphorylation caused by insulin and Ang II.

The classical pathway that has been described for mTOR/S6K-1 activation implies PI3K/Akt activation [40]. For this reason, we determined whether insulin- and Ang II-induced S6K-1 and IRS-1 phosphorylation were PI3K-dependent. As shown in Fig. 3D, when cells were exposed to 100 nM wortmannin (a selective PI3K inhibitor) for 30 min, the phosphorylation of S6K-1 Thr⁴²¹/Ser⁴²⁴ and IRS-1 Ser⁶³⁶/Ser⁶³⁹ by both hormones was totally inhibited. Similar results were obtained when LY-294002, another selective PI3K inhibitor, was employed (data not shown). This indicated that insulin and Ang II exert their effects on IRS-1 phosphorylation through the PI3K/mTOR/S6K-1 signaling pathway.

3.5. Ang II promotes S6K-1 and IRS-1 phosphorylation by EGF receptor transactivation

The above results have shown that Ang II induces IRS-1 Ser⁶³⁶/Ser⁶³⁹ phosphorylation through the PI3K/mTOR/S6K-1 pathway, similar to the manner in which insulin does so. However, there remains the question of how Ang II activates the PI3K/mTOR/S6K-1 pathway and induces IRS-1 Ser⁶³⁶/Ser⁶³⁹ phosphorylation and Akt inactivation in C9 cells.

In this context, previous studies in C9 cells have shown that Ang II-induced activation of the AT₁R causes PI3K/Akt activation by transactivating the EGFR [41,42]. This transactivation pathway is mediated by PKC/Src-dependent activation of transmembrane matrix metalloproteases (MMPs), which release heparin-binding EGF (HB-EGF) that causes activation of the EGFR [19,43]. To determine whether Ang II-induced IRS-1 and S6K-1 phosphorylation are due to AT₁R-mediated EGFR transactivation, cells were exposed to the AT₁ receptor antagonist DuP 753, and specific inhibitors of EGFR tyrosine kinase activity

(AG1478), MMPs (Galardin, GM6001) and PKC (Bisindolylmaleimide I, BIM) for 30 min, in the presence or absence of 100 nM Ang II or 100 nM insulin. Consistent with our previous reports showing that Ang II exerts its effects through activation of AT₁R in C9 cells [16,42], Ang II-induced S6K-1 and -IRS-1 phosphorylation was completely inhibited with 10 μ M DuP 753 (Fig. 4A and B, respectively). However, phosphorylation of both proteins was not altered when cells were stimulated with insulin in the presence of an AT₁R antagonist (Fig. 4A and B). The use of specific inhibitors to block AT₁R-induced EGFR transactivation confirmed that Ang II/AT₁R-induced S6K-1 Thr⁴²¹/Ser⁴²⁴ and IRS-1 Ser⁶³⁶/Ser⁶³⁹ phosphorylation are dependent on activation of PKC, MMPs and EGFR transactivation (Fig. 5A–D).

3.6. Activation of ERK1/2 by Ang II promotes S6K-1 and IRS-1 phosphorylation

We next evaluated the role of ERK1/2 activation in Ang II-induced S6K-1 and IRS-1 phosphorylation, since recent evidence suggests that ERK1/2 represents a direct upstream S6K-1 kinase involved in its phosphorylation and activation [44,45]. For this purpose, C9 cells were pretreated with the selective MEK1/2 inhibitor PD98059 (1 μ M), and stimulated with 100 nM Ang II or 100 nM insulin for 15 min. As expected, both insulin- and Ang II-induced ERK1/2 phosphorylation were completely inhibited when cells were exposed to PD98059 (Fig. 6A). Interestingly, the MEK1/2 inhibitor also completely inhibited only the Ang II-induced IRS-1 and S6K-1 phosphorylation and not those induced by insulin (Fig. 6B and C, respectively). These data strongly suggest a critical role of ERK1/2 in Ang II-induced S6K-1 and IRS-1 phosphorylation. Since our data did not rule out the involvement of PI3K in the activation of S6K-1, we next determined if ERK1/2 is a downstream effector of the PI3K/Akt pathway. For this we examined the effect of wortmannin on Ang II-induced ERK1/2 phosphorylation. As shown in Fig. 7, wortmannin blocked Ang II-induced ERK1/2 phosphorylation, but had no effect on insulin-induced ERK1/2 phosphorylation. Taken together, these data suggest that Ang II-induced ERK1/2 phosphorylation is downstream of PI3K and its activation is necessary for Ang II-induced S6K-1 Thr⁴²¹/Ser⁴²⁴ and IRS-1 Ser⁶³⁶/Ser⁶³⁹ phosphorylation.

3.7. The inhibitory effect of Ang II on Akt and GSK-3 is mediated by IRS-1 Ser⁶³⁶/Ser⁶³⁹ phosphorylation

Our results demonstrate that Ang II-induced S6K-1 activation and the subsequent phosphorylation of IRS-1 Ser⁶³⁶/Ser⁶³⁹ are mediated by EGFR transactivation through PI3K/ERK/mTOR. To determine whether this signaling mechanism is responsible for inhibition of Akt and GSK-3 α/β , C9 cells were exposed to specific kinase inhibitors (1 μ M AG1478, 1 μ M GM6001, 1 μ M BIM), then treated with 100 nM Ang II for 15 or 60 min and stimulated with 100 nM insulin for an additional 15 min. Insulin-stimulated Akt Thr³⁰⁸ (Fig. 8) and GSK-3 α/β (data not shown) phosphorylation was not affected, indicating that Ang II/AT₁R-mediated EGF receptor transactivation is necessary for the inhibitory effect of Ang II on insulin-induced Akt Thr³⁰⁸ and GSK-3 α/β phosphorylation.

Since wortmannin and LY-294002 inhibit at the level of PI3K to modulate Akt activity, we could not directly evaluate the involvement of PI3K in Ang II-induced Akt Thr³⁰⁸ inhibition because both compounds also inhibit insulin-induced Akt Thr³⁰⁸ (Fig. 8) and GSK-3 α/β

(data not shown) phosphorylation [31]. However, rapamycin, which inhibits the downstream effector of PI3K, mTOR/S6K-1, blocked the inhibitory effect of Ang II (Figs. 8 and Fig. 9), suggesting the involvement of the PI3K/mTOR/S6K-1 pathway in the inhibitory effect on Akt Thr³⁰⁸ and GSK-3 α / β phosphorylation.

The role of MEK/ERK in the Ang II-induced activation of S6K-1 and IRS-1 phosphorylation observed above suggested its participation in the development of insulin resistance. To investigate the role of MEK/ERK in the Ang II-induced inhibition of Akt activity and GSK-3 α / β , C9 cells were exposed to PD98059 for 30 min, treated with Ang II (100 nM for 15 or 60 min) and stimulated with insulin for 15 min. The MEK inhibitor was found to inhibit the effect of Ang II (Figs. 8 and Fig. 9), indicating that its inhibitory effect on Akt Thr³⁰⁸ and GSK-3 α / β phosphorylation involves the MEK/ERK1/2 pathway.

It has been recently shown that Ser⁶³⁶/Ser⁶³⁹ phosphorylation of IRS-1 triggers its degradation in response to insulin, as a homologous desensitization mechanism [35,36]. To determine if this mechanism is also involved in Ang II-induced Akt Thr³⁰⁸ inhibition, we evaluated the effect of insulin or Ang II treatment on IRS-1 protein integrity. When C9 cells were exposed to 100 nM insulin or 100 nM Ang II, and IRS-1 protein integrity was evaluated with an anti-IRS-1 antibody, insulin treatment reduced IRS-1 protein by about 44% as detected by Western blot analysis. Interestingly, Ang II treatment from 60 to 180 min also diminished IRS-1 protein by about 40% (Fig. 10A). When cells were pretreated with specific inhibitors of Ang II signaling, such as DuP 753, PD98059 or rapamycin, the degradative effect of Ang II on IRS-1 protein was inhibited (Fig. 10C).

It is known that various cellular proteins of the insulin signaling process, including IRS-1, are tightly regulated by proteolysis through proteasome in response to external signaling molecules [35,36]. For this reason, we sought to determine whether proteasome-mediated degradation is involved in the insulin- and Ang II-dependent decline of the IRS-1 level. To address this question, serum-starved C9 cells were cultured with Ang II in the presence or absence of the proteasome inhibitor, lactacystin. As shown in Fig. 10B and C, such proteasome inhibition caused marked stabilization of IRS-1 despite insulin and Ang II stimulation. This finding indicated that IRS-1 is regulated through proteasome-mediated degradation, which is triggered by Ang II stimulation. This decrease in IRS-1 protein may explain the inhibitory effect of Ang II treatment for 60 min on Akt Thr³⁰⁸ phosphorylation, although IRS-1 Ser⁶³⁶/Ser⁶³⁹ phosphorylation is absent.

4. Discussion

In the present study, we employed the rat hepatic C9 cell model, to investigate the effect of Ang II on insulin signaling, focusing on the insulin-induced regulation of Akt and GSK-3 α / β , key proteins involved in insulin signaling. The C9 cells employed in our study are derived from the normal rat liver and retain an epithelial phenotype. They also express endogenous AT₁Rs and IRs and provide a useful model for studies on the individual and interacting signaling mechanisms of GPCRs and RTKs [16–19,43,46–49]. Our results show that Ang II, upon transactivation of the EGFR, inhibits insulin-induced Akt activation through phosphorylation of IRS-1 at Ser⁶³⁶/Ser⁶³⁹ and its subsequent proteasomal

degradation by a mechanism that depends on the PI3K/ERK1/2/mTOR/S6K-1 signaling pathway.

Activation of Akt by insulin is a multistep process that for full activation requires hierarchical phosphorylation of two residues, the Thr³⁰⁸ in the activation loop within the kinase domain, and the Ser⁴⁷³ in the C-terminal of the kinase domain [4]. The phosphorylation of both sites is mediated by the actions of PDK1 and PDK2 (mTORC2), respectively [31,50–52]. Interestingly, several reports have suggested that each phosphorylation site performs different tasks in insulin action. Mutation of Thr³⁰⁸ to Ala blocks its activation, indicating that phosphorylation of this residue is required for Akt activation. On the other hand, mutation of Ser⁴⁷³ into Ala only partially inhibits Akt activation, suggesting that Ser⁴⁷³ phosphorylation is required for maximal kinase activation [50,53,54]. Moreover, several studies have demonstrated that phosphorylation of Thr³⁰⁸ is necessary for insulin-induced glucose uptake, whereas phosphorylation of Ser⁴⁷³ is not required [31,34,55].

We observed in C9 cells that insulin induced, as expected, phosphorylation of Akt at Thr³⁰⁸ and Ser⁴⁷³. When cells were exposed to Ang II, phosphorylation at both sites was impaired. Interestingly, the inhibitory effect of Ang II was higher in insulin-induced Thr³⁰⁸ phosphorylation than in Ser⁴⁷³. In this context, Akt phosphorylation at Thr³⁰⁸ has been implicated in the metabolic actions of insulin. Bayascas et al. [31] reported that knock-in mice expressing a mutant of PDK1 incapable of binding phosphoinositides were unable to activate Akt. Inhibition of Akt action resulted from reduced phosphorylation of Thr³⁰⁸, without affecting Ser⁴⁷³ phosphorylation. Interestingly, the knock-in mice are significantly small, insulin resistant, and hyperinsulinemic, correlating these abnormalities with defective PDK1 and the impairment of Akt phosphorylation at Thr³⁰⁸ [31]. Similarly, Kondapaka et al. [34] reported that 7-hydroxystaurosporine induces clinical insulin resistance by blocking Akt activation and subsequent GLUT4 translocation in response to insulin, and this effect appears to occur by inhibiting Thr³⁰⁸ phosphorylation without affecting Ser⁴⁷³ phosphorylation. Considering that phosphorylation of Akt at Thr³⁰⁸ appears to have important roles in insulin action, the ability of Ang II to impair insulin-induced phosphorylation at Thr³⁰⁸ suggests that it could be important in impairment of the metabolic actions of insulin.

One of the major targets of activated Akt is GSK-3 [56,57], which has an important role in the regulation of glycogen synthesis via inhibitory phosphorylation of glycogen synthase (GS). Upon insulin-mediated phosphorylation on Ser^{21/9} of the two isoforms of GSK-3, GSK-3 α and GSK-3 β , respectively, GSK-3 is inactivated [56,57]. This inactivation, in parallel to protein phosphatase-1 activation, relieves the inhibitory phosphorylation of GS, which becomes activated and promotes glycogen synthesis [57,58]. To evaluate the metabolic impairment caused by Ang II as a consequence of its inhibitory effect on Akt, we determined its effect on insulin-induced GSK-3 α/β Ser^{21/9} phosphorylation. Our results showed that AT₁R activation in C9 cells causes a reduction in insulin-induced GSK-3 α/β Ser^{21/9} phosphorylation, affecting hepatic glycogen synthesis, and are consistent with the results observed in the transgenic REN2 rat, an experimental model of excessive tissue local RAS activity with severe cardiovascular and metabolic defects, where insulin-stimulated

glucose-transport activity, GSK-3 phosphorylation and glycogen synthesis are substantially reduced [59].

Initial attempts to unravel the molecular mechanism of insulin resistance strongly suggested that a defect responsible for this is located at the post-receptor level of insulin signaling [29]. A mechanism that recently emerged as a potential explanation proposed that serine phosphorylation of IRS-1 proteins can reduce their ability to attract PI3K, minimizing its activation [29,60]. A number of serine kinases that phosphorylate serine residues of IRS-1 and weaken insulin signal transduction have been identified, such as the insulin-induced activation of mTOR and S6K-1 [12,33,61].

The mTOR pathway and its downstream target S6K-1 integrate insulin and nutrient signaling in numerous cell types. Recent studies suggest that this pathway also acts as a homologous desensitization mechanism (negative feedback loop) that negatively regulates insulin signaling to PI3K/Akt in insulin target tissues [27,33,62]. In this context, Um et al. [33] recently demonstrated that S6K-1-deficient mice are hypersensitive to insulin due to loss of the negative feedback loop from S6K-1 to IRS-1, and are protected from age- and diet-induced obesity [33]. In genetic models of obesity, such as K/K^{ay} and ob/ob mice, insulin signaling is suppressed with increased phosphorylation of Ser³⁰⁷ and Ser⁶³⁶/Ser⁶³⁹ in IRS-1 [33]. In such mice, the activities of JNK and mTOR/S6K-1, which can phosphorylate serine residue(s) of IRS-1, were reported to be elevated [33,63]. Khamzina et al. [27] also showed that the mTOR/S6K-1 cascade was over-stimulated and insulin-induced Akt activation was inhibited in the livers of rats fed with a high fat diet.

Because of the relevance of the PI3K/S6K-1 pathway in the regulation of insulin signaling, we determined whether Ang II could induce S6K-1 activation in C9 cells and if this may lead to IRS-1 Ser⁶³⁶/Ser⁶³⁹ phosphorylation and thus explain the inhibitory effect on Akt and its downstream substrate GSK-3. We observed that Ang II induced a transitory increase in IRS-1 Ser⁶³⁶/Ser⁶³⁹ and S6K-1 Thr⁴²¹/Ser⁴²⁴ phosphorylation. Ang II-induced phosphorylation of both proteins was rapamycin- and wortmannin-dependent, suggesting the involvement of the PI3K/mTOR/S6K-1 pathway.

Our results are in agreement with previous findings that have shown that Ang II induces IRS-1 serine phosphorylation as a key mechanism to desensitize insulin signaling. For example, Izawa et al. [24] found that Ang II-induced JNK and ERK1/2 activation causes serine phosphorylation of IRS-1 at both 307 and 616, and inhibits insulin-induced IRS-1 tyrosine phosphorylation in RASMC. In HUVEC cells, Andreozzi et al. [23] reported that Ang II activates JNK and MAP-kinase pathways, leading to increased serine phosphorylation of IRS (Ser³¹² and Ser⁶¹⁶, respectively), impaired insulin-induced PI3K/Akt/eNOS signaling pathway, and endothelial dysfunction. In rat aortic smooth muscle cells (RASMCs), it has been shown that Ang II impairs insulin-mediated IRS-1 tyrosine phosphorylation by a mechanism that involves an increased phosphorylation of the IR, IRS and the p85 subunit of PI3K on Ser residues [64]. In addition, Motley et al. showed that Ang II inhibits insulin-induced activation of Akt by blocking IRS-1 function through PKC α activation [25]. However, none of these studies has pointed out the role of Ang II-

induced S6K-1 activation in the regulation of insulin signaling through phosphorylation of IRS-1 at Ser⁶³⁶/Ser⁶³⁹.

We have previously described that Ang II induces PI3K and ERK1/2 activation in C9 cells by a mechanism that depends exclusively on EGFR transactivation [16,18,19,65]. Thus, we also determined whether EGFR transactivation could unleash the Ang II-induced activation of PI3K/mTOR/S6K-1 pathway to desensitize insulin signaling. Our results showed that Ang II induces EGF receptor transactivation that leads to the phosphorylation of S6K-1 and IRS-1 by the mechanism previously described that requires PKC/Src/MMP activation and release of the HB-EGF endogenous ligand of EGFR [19]. Although the ability of Ang II to activate S6K-1 through EGFR transactivation was previously described [66,67], our results demonstrate for the first time that Ang II-induced S6K-1 activation is able to impair insulin signaling by increasing serine phosphorylation of IRS-1, specifically at Ser⁶³⁶/Ser⁶³⁹.

Many recent studies have been focused on the mechanisms involved in the regulation of S6K-1. New insights into this research suggest the involvement of different pathways, including the classical PI3K/mTOR and the PKC/cRAF/MEK1/2/ERK1/2 sequence. Since AT₁Rs expressed in the C9 cell model are coupled to both signaling pathways, we tested for cross-talk between the ERK and the S6K-1 pathways and found that the specific PI3K inhibitors, wortmannin and LY-294002, inhibited Ang II-induced ERK1/2 activation. Interestingly, we found that the MEK1/2 inhibitor PD98059 could inhibit not only Ang II-induced ERK1/2 phosphorylation but also the S6K-1 and IRS-1 phosphorylation. These data revealed that ERK1/2 could have a role in Ang II-induced S6K-1 and IRS-1 phosphorylation. Although we demonstrate here that Ang II-induced ERK1/2 can be a downstream target of PI3K, previous reports have shown PI3K dependence for ERK1/2 activation. In this context, Tanski et al.[68] showed that smooth muscle cell migration induced by sphingosine-1-phosphate is dependent on ERK1/2 activation that is mediated by PI3K. Similarly, Punnett et al. [69] showed in human embryonic kidney 293 cells that UCN-1, acting through its CRH-R₁-α receptor, induces ERK1/2 activation that is dependent on both PI3K/Akt and EGF receptor activation. These data provide evidence for a new mechanism for Ang II-induced S6K-1 activation that leads to IRS-1 Ser⁶³⁶/Ser⁶³⁹ phosphorylation, involving AT₁ receptor mediated-EGFR transactivation and subsequent activation of the PI3K/ERK1/2/mTOR/S6K-1 pathway.

We report here that Ang II-induced IRS-1 Ser⁶³⁶/Ser⁶³⁹ phosphorylation by S6K-1 is involved in the inhibition of Akt. The importance of the mTOR/S6K-1 pathway in the development of insulin resistance has been previously described. Ueno et al. [70] showed that chronic hyperinsulinemia itself decreases insulin signaling in the liver and muscle of rats, and increases mTOR/S6K-1 activity and Ser phosphorylation of IRS-1/2. In addition, rapamycin-induced inhibition of the mTOR signaling pathway prevents the insulin resistance caused by chronic hyperinsulinemia in liver and muscle [70].

We observed that at 60 min Ang II was unable to induce IRS-1 phosphorylation, while retaining the inhibitory effect on Akt activation. This can be explained because Ang II can induce IRS-1 protein degradation as observed in Fig. 10. Previous reports have shown that Ser/Thr phosphorylation of IRS-1 protein can induce its degradation, specifically by a

mechanism that involves IRS-1 phosphorylation at Ser⁶³⁶/Ser⁶³⁹ [36]. In addition, it has been suggested that insulin-induced IRS-1 degradation is mediated by a rapamycin-sensitive pathway [35].

In summary, our findings indicate that Ang II impairs insulin-induced Akt Thr³⁰⁸ phosphorylation by increasing IRS-1 Ser⁶³⁶/Ser⁶³⁹ phosphorylation and IRS-1 protein degradation, by a mechanism dependent on EGF transactivation that leads to PI3K/ERK1/2/mTOR/S6K-1 activation (Fig. 11). These findings provide evidence that defines a role of Ang II in the development of insulin resistance.

Acknowledgments

This research was supported by Cinvestav-IPN and CONACYT/ SEP Research Grants 39485-Q/48777 (to J.A. O.-R.); by CONACYT fellowship grant, No. 169944 and Apoyo Integral para la Formación de Doctores en Ciencia, Modalidad A, Tesista de Doctorado, CONACYT (to A. A.-P.). The authors thank Norma Cirnes for her help in the preparation of the figures.

Abbreviations

Ang II	angiotensin II
AT₁R	angiotensin type 1 receptor
EGF	epidermal growth factor
GPCRs	G protein-coupled receptors
GSK-3	glycogen synthase kinase-3
IRS	insulin receptor substrate
IR	insulin receptor
mTOR	mammalian target of rapamycin
PI3K	phosphatidylinositol 3-kinase
RAS	renin-angiotensin system
S6K-1	ribosomal S6 kinase-1

References

1. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. *Nature*. 2001; 414:799–806. [PubMed: 11742412]
2. Myers, MG., Jr; White, MF. The molecular basis of insulin action. In: Gruenberg, G.; Zick, Y., editors. *Insulin signaling: from cultured cells to animal models*. New York: Taylor & Francis; 2002. p. 55-87.
3. Kido Y, Nakae J, Accili D. Clinical review 125: the insulin receptor and its cellular targets. *J Clin Endocrinol Metab*. 2001; 86:972–979. [PubMed: 11238471]
4. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. *Cell*. 2007; 129:1261–1274. [PubMed: 17604717]
5. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: implications for diabetes. *Mol Cell Endocrinol*. 2009; 302:128–139. [PubMed: 19150387]

6. Le Roith, D.; Quon, MJ.; Zick, Y. Molecular and cellular aspects of insulin resistance: implications for diabetes. In: Finkel, T.; Gutkind, JS., editors. *Signal transduction and human disease*. Hoboken, NJ: Wiley-Interscience; 2003. p. 171-200.
7. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. *Endocr Rev*. 2007; 28:463–491. [PubMed: 17525361]
8. Riccardi G, Giacco R, Rivelles AA. Dietary fat, insulin sensitivity and the metabolic syndrome. *Clin Nutr*. 2004; 23:447–456. [PubMed: 15297079]
9. Reaven G, Abbasi F, McLaughlin T. Obesity, insulin resistance, and cardiovascular disease. *Recent Prog Horm Res*. 2004; 59:207–223. [PubMed: 14749503]
10. Zick Y. Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. *Sci STKE*. 2005:e4. 2005.
11. Usui I, Imamura T, Babendure JL, Satoh H, Lu JC, Hupfeld CJ, et al. G protein-coupled receptor kinase 2 mediates endothelin-1-induced insulin resistance via the inhibition of both G α q/11 and insulin receptor substrate-1 pathways in 3T3-L1 adipocytes. *Mol Endocrinol*. 2005; 19:2760–2768. [PubMed: 15994203]
12. Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, et al. A molecular basis for insulin resistance Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. *J Biol Chem*. 1997; 272:29911–29918. [PubMed: 9368067]
13. Mason TM, Goh T, Tchipashvili V, Sandhu H, Gupta N, Lewis GF, et al. Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats. *Diabetes*. 1999; 48:524–530. [PubMed: 10078552]
14. Carnevali JB, Calegari VC, Zecchin HG, Nadruz W Jr, Guimaraes RB, Ribeiro EB, et al. The cross-talk between angiotensin and insulin differentially affects phosphatidylinositol 3-kinase- and mitogen-activated protein kinase-mediated signaling in rat heart: implications for insulin resistance. *Endocrinology*. 2003; 144:5604–5614. [PubMed: 12960006]
15. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. *Mol Endocrinol*. 2006; 20:953–970. [PubMed: 16141358]
16. García-Sáinz JA, García-Caballero A, González-Espinosa C. Angiotensin AT1 receptors in clone 9 rat liver cells: Ca²⁺ signaling and c-fos expression. *Eur J Pharmacol*. 1998; 362:235–243. [PubMed: 9874176]
17. Olivares-Reyes JA, Shah BH, Hernandez-Aranda J, Garcia-Caballero A, Far-shori MP, Garcia-Sainz JA, et al. Agonist-induced interactions between angiotensin AT1 and epidermal growth factor receptors. *Mol Pharmacol*. 2005; 68:356–364. [PubMed: 15905421]
18. Shah BH, Olivares-Reyes JA, Yesilkaya A, Catt KJ. Independence of angiotensin II-induced MAP kinase activation from angiotensin type 1 receptor internalization in clone 9 hepatocytes. *Mol Endocrinol*. 2002; 16:610–620. [PubMed: 11875120]
19. Shah BH, Yesilkaya A, Olivares-Reyes JA, Chen HD, Hunyady L, Catt KJ. Differential pathways of angiotensin II-induced extracellularly regulated kinase 1/2 phosphorylation in specific cell types: role of heparin-binding epidermal growth factor. *Mol Endocrinol*. 2004; 18:2035–2048. [PubMed: 15143154]
20. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonist reduces insulin resistance in obese Zucker rats. *Hypertension*. 2001; 38:884–890. [PubMed: 11641303]
21. Kudoh A, Matsuki A. Effects of angiotensin-converting enzyme inhibitors on glucose uptake. *Hypertension*. 2000; 36:239–244. [PubMed: 10948084]
22. Henriksen EJ. Improvement of insulin sensitivity by antagonism of the renin- angiotensin system. *Am J Regul Integr Comp Physiol*. 2007; 293:R974–R980.
23. Andreozzi F, Laratta E, Sciacqua A, Perticone F, Sesti G. Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. *Circ Res*. 2004; 94:1211–1218. [PubMed: 15044323]

24. Izawa Y, Yoshizumi M, Fujita Y, Ali N, Kanematsu Y, Ishizawa K, et al. ERK1/2 activation by angiotensin II inhibits insulin-induced glucose uptake in vascular smooth muscle cells. *Exp Cell Res*. 2005; 308:291–299. [PubMed: 15921682]
25. Motley ED, Eguchi K, Gardner C, Hicks AL, Reynolds CM, Frank GD, et al. Insulin-induced Akt activation is inhibited by angiotensin II in the vasculature through protein kinase C- α . *Hypertension*. 2003; 41:775–780. [PubMed: 12623995]
26. Morino K, Petersen KF, Dufour S, Befroy D, Frattini J, Shatzkes N, et al. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. *J Clin Invest*. 2005; 115:3587–3593. [PubMed: 16284649]
27. Khamzina L, Veilleux A, Bergeron S, Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. *Endocrinology*. 2005; 146:1473–1481. [PubMed: 15604215]
28. Marrero MB, Fulton D, Stepp D, Stern DM. Angiotensin II-induced insulin resistance and protein tyrosine phosphatases. *Arterioscler Thromb Vasc Biol*. 2004; 24:2009–2013. [PubMed: 15271787]
29. Schinner S, Scherbaum WA, Bornstein SR, Barthel A. Molecular mechanisms of insulin resistance. *Diabet Med*. 2005; 22:674–682. [PubMed: 15910615]
30. Wei Y, Sowers JR, Nistala R, Gong H, Uptergrove GME, Clark SE, et al. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. *J Biol Chem*. 2006; 281:35137–35146. [PubMed: 16982630]
31. Bayascas JR, Wulschleger S, Sakamoto K, Garcia-Martinez JM, Clacher C, Komander D, et al. Mutation of the PDK1 PH domain inhibits protein kinase B/Akt, leading to small size and insulin resistance. *Mol Cell Biol*. 2008; 28:3258–3272. [PubMed: 18347057]
32. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. *J Hepatol*. 2007; 47:142–156. [PubMed: 17512085]
33. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. *Nature*. 2004; 431:200–205. [PubMed: 15306821]
34. Kondapaka SB, Zarnowski M, Yver DR, Sausville EA, Cushman SW. 7-hydro-xystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylation: a basis for decreased insulin-stimulated glucose transport. *Clin Cancer Res*. 2004; 10:7192–7198. [PubMed: 15534092]
35. Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM, et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. *Mol Endocrinol*. 2000; 14:783–794. [PubMed: 10847581]
36. Pederson TM, Kramer DL, Rondinone CM. Serine/threonine phosphorylation of IRS-1 triggers its degradation: possible regulation by tyrosine phosphorylation. *Diabetes*. 2001; 50:24–31. [PubMed: 11147790]
37. Gual P, Gremeaux T, Gonzalez T, Le Marchand-Brustel Y, Tanti JF. MAP kinases and mTOR mediate insulin-induced phosphorylation of insulin receptor substrate-1 on serine residues 307, 612 and 632. *Diabetologia*. 2003; 46:1532–1542. [PubMed: 14579029]
38. Dufner A, Thomas G. Ribosomal S6 kinase signaling and the control of translation. *Exp Cell Res*. 1999; 253:100–109. [PubMed: 10579915]
39. Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. *J Cell Biol*. 2004; 167:399–403. [PubMed: 15533996]
40. Hay N, Sonenberg N. Upstream and downstream of mTOR. *Genes Dev*. 2004; 18:1926–1945. [PubMed: 15314020]
41. Shah BH, Shah FB, Catt KJ. Role of metalloproteinase-dependent EGF receptor activation in alpha-adrenoceptor-stimulated MAP kinase phosphorylation in GT1-7 neurons. *J Neurochem*. 2006; 96:520–532. [PubMed: 16336626]
42. García-Caballero A, Olivares-Reyes JA, Catt KJ, García-Sáinz JA. Angiotensin AT(1) receptor phosphorylation desensitization in a hepatic cell line Roles of protein kinase c and phosphoinositide 3-kinase. *Mol Pharmacol*. 2001; 59:576–585. [PubMed: 11179453]

43. Shah BH, Neithardt A, Chu DB, Shah FB, Catt KJ. Role of EGF receptor trans-activation in phosphoinositide 3-kinase-dependent activation of MAP kinase by GPCRs. *J Cell Physiol.* 2006; 206:47–57. [PubMed: 15920762]
44. Rolfe M, McLeod LE, Pratt PF, Proud CG. Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2). *Biochem J.* 2005; 388:973–984. [PubMed: 15757502]
45. Wang L, Gout I, Proud CG. Cross-talk between the ERK and p70 S6 kinase (S6K) signaling pathways MEK-dependent activation of S6K2 in cardiomyocytes. *J Biol Chem.* 2001; 276:32670–32677. [PubMed: 11431469]
46. Quintanilla RA, Porras OH, Castro J, Barros LF. Cytosolic $[Ca^{2+}]$ modulates basal GLUT1 activity and plays a permissive role in its activation by metabolic stress and insulin in rat epithelial cells. *Cell Calcium.* 2000; 28:97–106. [PubMed: 10970766]
47. Shah BH, Catt KJ. Calcium-independent activation of extracellularly regulated kinases 1 and 2 by angiotensin II in hepatic C9 cells: roles of protein kinase C delta, Src/proline-rich tyrosine kinase 2, and epidermal growth receptor trans-activation. *Mol Pharmacol.* 2002; 61:343–351. [PubMed: 11809859]
48. Shetty M, Kuruvilla AK, Ismail-Beigi F, Loeb JN. Stimulation of glucose trans-transport in Clone9 cells by insulin and thyroid hormone: role of GLUT-1 activation. *Biochim Biophys Acta.* 1996; 1314:140–146. [PubMed: 8972727]
49. Nellis MM, Doering CB, Kasinski A, Danner DJ. Insulin increases branched-chain alpha-ketoacid dehydrogenase kinase expression in Clone9 rat cells. *Am J Physiol Endocrinol Metab.* 2002; 283:E853–E860. [PubMed: 12217904]
50. Chan TO, Tsichlis PN. PDK2: a complex tail in one Akt. *Sci STKE.* 2001;E1. 2001.
51. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. *Science.* 2005; 307:1098–1101. [PubMed: 15718470]
52. Bayascas JR, Alessi DR. Regulation of Akt/PKB Ser473 phosphorylation. *Mol Cell.* 2005; 18:143–145. [PubMed: 15837416]
53. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. *EMBO J.* 1996; 15:6541–6551. [PubMed: 8978681]
54. Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D, et al. Akt activation by growth factors is a multiple-step process: the role of the PH domain. *Oncogene.* 1998; 17:313–325. [PubMed: 9690513]
55. Morisco C, Condorelli G, Trimarco V, Bellis A, Marrone C, Condorelli G, et al. Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. *Circ Res.* 2005; 96:180–188. [PubMed: 15591229]
56. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature.* 1995; 378:785–789. [PubMed: 8524413]
57. Frojdo S, Vidal H, Pirola L. Alterations of insulin signaling in type 2 diabetes: a review of the current evidence from humans. *Biochim Biophys Acta.* 2009; 1792:83–92. [PubMed: 19041393]
58. Brady MJ, Bourbonais FJ, Saltiel AR. The activation of glycogen synthase by insulin switches from kinase inhibition to phosphatase activation during adipogenesis in 3T3-L1 cells. *J Biol Chem.* 1998; 273:14063–14066. [PubMed: 9603900]
59. Sloniger JA, Saengsirisuwan V, Diehl CJ, Dokken BB, Lailerd N, Lemieux AM, et al. Defective insulin signaling in skeletal muscle of the hypertensive TG(mREN2)27 rat. *Am J Physiol Endocrinol Metab.* 2005; 288:E1074–E1081. [PubMed: 15657091]
60. Shulman GI. Cellular mechanisms of insulin resistance. *J Clin Invest.* 2000; 106:171–176. [PubMed: 10903330]
61. Mothe I, Van OE. Phosphorylation of insulin receptor substrate-1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action. *J Biol Chem.* 1996; 271:11222–11227. [PubMed: 8626671]
62. Um SH, D'Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. *Cell Metab.* 2006; 3:393–402. [PubMed: 16753575]

63. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, et al. A central role for JNK in obesity and insulin resistance. *Nature*. 2002; 420:333–336. [PubMed: 12447443]
64. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. *J Clin Invest*. 1997; 100:2158–2169. [PubMed: 9410892]
65. Shah BH. Epidermal growth factor receptor transactivation in angiotensin II-induced signaling: role of cholesterol-rich microdomains. *Trends Endocrinol Metab*. 2002; 13:1–2. [PubMed: 11750852]
66. Chiu T, Santiskulvong C, Rozengurt E. EGF receptor transactivation mediates ANG II-stimulated mitogenesis in intestinal epithelial cells through the PI3-kinase/Akt/mTOR/p70S6K1 signaling pathway. *Am J Physiol Gastrointest Liver Physiol*. 2005; 288:G182–G194. [PubMed: 15358595]
67. Eguchi S, Iwasaki H, Ueno H, Frank GD, Motley ED, Eguchi K, et al. Intracellular signaling of angiotensin II-induced p70 S6 kinase phosphorylation at Ser(411) in vascular smooth muscle cells Possible requirement of epidermal growth factor receptor, Ras, extra cellular signal-regulated kinase, and Akt. *J Biol Chem*. 1999; 274:36843–36851. [PubMed: 10601235]
68. Tanski W, Roztocil E, Davies MG. Sphingosine-1-phosphate induces G(alpha i)-coupled, PI3K/ras-dependent smooth muscle cell migration. *J Surg Res*. 2002; 108:98–106. [PubMed: 12443721]
69. Punj A, Levine MA, Grammatopoulos DK. Identification of signaling molecules mediating corticotropin-releasing hormone-R1alpha-mitogen-activated protein kinase (MAPK) interactions: the critical role of phosphatidylinositol 3-kinase in regulating ERK1/2 but not p38 MAPK activation. *Mol Endocrinol*. 2006; 20:3179–3195. [PubMed: 16959871]
70. Ueno M, Carvalheira JB, Tambascia RC, Bezerra RM, Amaral ME, Carneiro EM, et al. Regulation of insulin signalling by hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway. *Diabetologia*. 2005; 48:506–518. [PubMed: 15692808]

Fig. 1.

Effect of Ang II on insulin-induced Akt and GSK-3 phosphorylation. C9 cells were treated with 100 nM insulin (A and B) for the indicated times, or pretreated with 100 nM Ang II from 5 to 60 min and then stimulated with 100 nM insulin for an additional 15 min (C and D). Total cell lysates were separated by SDS-PAGE and analyzed by immunoblotting with anti-p-Akt Ser⁴⁷³, anti-p-Akt Thr³⁰⁸ or anti-p-GSK-3 α/β Ser^{21/9} as described in Section 2. Vertical lines represent the S.E.M. The right panels show representative immunoblots. Western blots were also probed for total Akt and GSK-3 β , showing equal loading. (A) **p* <

0.001 and $**p < 0.01$ vs time 0 (control). (B) $*p < 0.01$ and $**p < 0.05$ vs time 0 (control). (C) $*p < 0.001$ vs insulin (–). (D) $*p < 0.001$ vs control; $**p < 0.001$ vs insulin. Con, control; Ins, insulin.

Fig. 2.

Ang II induces IRS-1 Ser⁶³⁶/Ser⁶³⁹ phosphorylation. (A) Cells were stimulated with 100 nM insulin or 100 nM Ang II for the indicated times. (B) Cells were exposed to the indicated concentration of Ang II for 15 min. Total cell lysates were separated by SDS-PAGE, and analyzed by immunoblotting with anti-p-IRS-1 Ser⁶³⁶/Ser⁶³⁹ as described in Section 2. Vertical lines represent the S.E.M. The right panels show representative immunoblots. Western blots were also probed for total IR showing equal loading. (A) * $p < 0.01$ and ** $p < 0.05$ vs time 0 (control). (B) * $p < 0.05$ vs time 0 (control). Ins, insulin.

Fig. 3.

PI3K/Akt/S6K-1 pathway mediates Ang II-induced IRS-1 Ser⁶³⁶/Ser⁶³⁹ phosphorylation.

(A) Cells were exposed to the indicated concentrations of Ang II or insulin for 15 min. (B) Cells were stimulated with 100 nM insulin or 100 nM Ang II for the indicated times. (C and D) Cells were pretreated with or without 100 nM rapamycin (C) or 100 nM wortmannin (D) for 30 min, before stimulation with 100 nM Ang II or 100 nM insulin for 15 min. Total cell lysates were separated by SDS-PAGE and analyzed by immunoblotting with anti-p-S6K-1 Thr⁴²¹/Ser⁴²⁴ or anti-p-IRS-1 Ser⁶³⁶/Ser⁶³⁹ as described under Section 2. Vertical lines

represent the S.E.M. The panels show representative immunoblots. Western blots were also probed for total S6K-1 showing equal loading. (A) $*p < 0.01$, $**p < 0.05$, and $***p < 0.001$ vs control. (B) $*p < 0.01$ and $**p < 0.05$ vs time 0 (control). Con, control; Ins, insulin; Rap, rapamycin; W, wortmannin.

Fig. 4.

Ang II acts through the AT₁ receptor. Cells were pretreated with or without 10 μ M DuP 753 for 30 min, before stimulation with 100 nM Ang II or 100 nM insulin for 15 min. Total cell lysates were separated by SDS-PAGE and analyzed with anti-p-S6K-1 Thr⁴²¹/Ser⁴²⁴ (A) or anti-p-IRS-1 Ser⁶³⁶/Ser⁶³⁹ (B) as described in Section 2. Vertical lines represent the S.E.M. The right panels show representative immunoblots for A and B. Western blots were also probed for total S6K-1 and IR showing equal loading. (A) * p < 0.01 vs control; ** p < 0.01 vs Ang II. (B) * p < 0.001 vs control; ** p < 0.001 vs Ang II. Con, control; Ins, insulin; DuP, DuP 753.

Fig. 5.

Transactivation of EGFRs by Ang II mediates IRS-1 and S6K-1 phosphorylation. C9 cells were pretreated with 1 μ M BIM (A and B), 1 μ M AG1478 or 1 μ M GM6001 (C and D) for 30 min, before stimulation with 100 nM Ang II (A–D) or 100 nM insulin (A and B) for 15 min, or 10 ng/ml EGF for 5 min (C and D). Total cell lysates were separated by SDS-PAGE and analyzed by immunoblotting with anti-p-S6K-1 Thr⁴²¹/Ser⁴²⁴ (A and C) or anti-p-IRS-1 Ser⁶³⁶/Ser⁶³⁹ (B and D) as described in Section 2. Vertical lines represent the S.E.M. The lower panels show representative immunoblots for A and B and C and D. Western blots

were also probed for total S6K-1 showing equal loading. (A) $*p < 0.001$ vs control; $**p < 0.001$ vs Ang II. (B) $*p < 0.01$ vs control; $**p < 0.05$ vs Ang II. (C and D) $*p < 0.001$ vs control; $**p < 0.001$ vs Ang II or EGF (-); $***p < 0.01$ vs Ang II (-). Con, control; Ins, Insulin; AG, AG1478; GM, GM6001.

Fig. 6.

ERK1/2 activation is involved in Ang II-induced IRS-1 Ser⁶³⁶/Ser⁶³⁹ and S6K-1 Thr⁴²¹/Ser⁴²⁴ phosphorylation. C9 cells were pretreated with or without 1 μ M PD98059 for 30 min, before stimulation with 100 nM Ang II or 100 nM insulin for 15 min. Total cell lysates were separated by SDS-PAGE and analyzed with anti-p-ERK1/2 Thr²⁰²/Tyr²⁰⁴ (A), anti-p-S6K-1 Thr⁴²¹/Ser⁴²⁴ (B) or anti-p-IRS-1 Ser⁶³⁶/Ser⁶³⁹ (C), as described in Section 2. Vertical lines represent the S.E.M. The lower panels show representative immunoblots for B and C. Western blots were also probed for total ERK1/2, S6K-1 and IR showing equal loading. (B and C) * $p < 0.001$ vs control; ** $p < 0.001$ vs Ang II. Con, control; Ins, insulin; PD, PD98059.

Fig. 7.

Ang II-induced ERK1/2 activation is downstream of PI3K. C9 cells were pretreated with or without 100 nM wortmannin for 30 min before stimulation with 100 nM Ang II or 100 nM insulin for 15 min. Total cell lysates were separated by SDS-PAGE, and analyzed with anti-p-ERK1/2 Thr²⁰²/Tyr²⁰⁴ as described in Section 2. Vertical lines represent the S.E.M. The lower panel shows a representative immunoblot. Western blots were also probed for total ERK1/2 showing equal loading. * $p < 0.01$ vs control; ** $p < 0.001$ vs Ang II. Con, control; Ins, insulin; W, wortmannin.

Fig. 8.

Inhibition of IRS-1 Ser⁶³⁶/Ser⁶³⁹ reverses inhibition of insulin-induced Akt Thr³⁰⁸ phosphorylation elicited by Ang II treatment for 15 min. C9 cells were pretreated with or without: 1 μ M AG1478, 1 μ M GM6001, 10 μ M LY-294002, 100 nM wortmannin, 100 nM rapamycin, 1 μ M BIM, 1 μ M PD98059, or 10 μ M DuP 753, for 30 min before treatment with 100 nM Ang II for 15 min (A) or 60 min (B) and then stimulated with 100 nM insulin for an additional 15 min. Total cell lysates were separated by SDS-PAGE, and analyzed with anti-p-Akt³⁰⁸ as described in Section 2. Vertical lines represent the S.E.M. The right panels show a representative immunoblot for A and B. Western blots were also probed for total Akt showing equal loading. (A) [#] $p < 0.001$ vs control; ^{*} $p < 0.001$ vs insulin; ^{**} $p < 0.05$, ^{***} $p < 0.001$, and ⁺ $p < 0.01$ vs Ang II + Ins (-). (B) [#] $p < 0.001$ vs control; ^{*} $p < 0.001$ vs insulin; ^{**} $p < 0.001$, ^{***} $p < 0.05$, and ⁺ $p < 0.01$ vs Ang II + Ins (-). Con, control; Ins, insulin; AG, AG1478; GM, GM6001; LY, LY-294002; W, wortmannin; Rap, rapamycin; PD, PD98059; DuP, DuP 753.

Fig. 9.

Inhibition of IRS-1 Ser⁶³⁶/Ser⁶³⁹ reverses inhibition of insulin-induced GSK-3α/β Ser^{21/9} phosphorylation elicited by Ang II treatment. C9 cells were pretreated with or without: 10 μM DuP 753, 100 nM rapamycin or 1 μM PD98059, for 30 min before treatment with 100 nM Ang II for 15 min (A) or 100 nM Ang II for 60 min (B) and then stimulated with 100 nM insulin for an additional 15 min. Total cell lysates were separated by SDS-PAGE, and analyzed with anti-pGSK-3α/β Ser^{21/9} as described in Section 2. Vertical lines represent the S.E.M. The lower panels show representative immunoblots for A and B. Western blots were also probed for total GSK-3β showing equal loading. (A) **p* < 0.001 vs control; ***p* < 0.001 vs Ins; +*p* < 0.05 and ****p* < 0.001 vs Ang II + Ins (-). (B) **p* < 0.01 vs control; ***p* < 0.01 vs Ins; ****p* < 0.05 vs Ang II + Ins (-). Con, control; Ins, insulin; DuP, DuP 753; PD, PD98059; Rap, rapamycin.

Fig. 10.

Ang II triggers degradation of IRS. (A) Cells were stimulated with 100 nM insulin or 100 nM Ang II from 15 to 180 min. Cells were pretreated with or without: 40 μ M lactacystin, 10 μ M DuP 753, 100 nM rapamycin or 1 μ M PD98059, for 30 min before treatment with 100 nM insulin (B) or 100 nM Ang II (C) for 15 or 180 min. Total cell lysates were separated by SDS-PAGE, and analyzed with anti-IRS-1 as described under Section 2. Vertical lines represent the S.E.M. The right panel shows a representative blot for A. Western blots were also probed for total IR or total RAF-1 showing equal loading. (A) ⁺ p < 0.05, ⁺⁺ p < 0.01, and ^{*} p < 0.05 vs time 0 (control). (B) ^{*} p < 0.01 vs control; ^{**} p < 0.001 vs insulin 3 h (-). (C) ^{*} p < 0.05 vs control; ^{**} p < 0.05 vs Ang II 3 h (-); ^{***} p < 0.01 vs Ang II 3 h (-). Con, control; Lac, lactacystin; Ins, insulin; PD, PD98059; DuP, DuP 753; Rap, rapamycin.

Fig. 11.

A model is presented whereby serine phosphorylation of IRS-1 serves as a mediator of Ang II to inhibit insulin-induced Akt Thr³⁰⁸ phosphorylation. When C9 cells are stimulated with Ang II, the endogenous AT₁R is activated leading to PKC/MMP-dependent release of the HB-EGF ligand, which in turn activates the EGFR. Such EGFR transactivation leads to activation of the PI3K/ERK1/2/mTOR/S6K-1 pathway, where S6K-1 has an important role in the phosphorylation and degradation of IRS-1, which impairs insulin-induced PI3K and Akt activation.